Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $50.11 Average PT from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $50.11.

A number of equities analysts have recently issued reports on the company. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Celldex Therapeutics in a research report on Friday, June 13th. UBS Group lowered their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. The Goldman Sachs Group dropped their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Morgan Stanley decreased their price objective on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Finally, Canaccord Genuity Group started coverage on shares of Celldex Therapeutics in a report on Monday, April 28th. They issued a "buy" rating and a $64.00 target price on the stock.

Institutional Trading of Celldex Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLDX. Rhumbline Advisers grew its stake in Celldex Therapeutics by 6.9% in the first quarter. Rhumbline Advisers now owns 98,266 shares of the biopharmaceutical company's stock valued at $1,784,000 after acquiring an additional 6,327 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company's stock worth $2,383,000 after purchasing an additional 14,979 shares in the last quarter. Millennium Management LLC grew its position in Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company's stock valued at $7,259,000 after purchasing an additional 306,330 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock valued at $798,000 after purchasing an additional 680 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in Celldex Therapeutics during the first quarter worth $265,000.

Celldex Therapeutics Stock Up 6.2%

Shares of NASDAQ CLDX traded up $1.26 during midday trading on Friday, reaching $21.65. 891,177 shares of the company were exchanged, compared to its average volume of 940,646. The stock's 50-day moving average price is $19.92 and its 200-day moving average price is $21.45. The stock has a market cap of $1.44 billion, a P/E ratio of -8.02 and a beta of 1.33. Celldex Therapeutics has a one year low of $14.40 and a one year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative return on equity of 23.46% and a negative net margin of 2,366.07%. On average, equities research analysts anticipate that Celldex Therapeutics will post -2.48 EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.